ANTI-PHOSPHO-GSK-3A SER21 CLONE 1E22 ZOOMAB RABBIT MONOCLONAL (C15-1670-372)

General description

We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies.

Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Specificity

Clone 1E22 is a ZooMAb^® Rabbit recombinant monoclonal antibody that specifically detects GSK-3a phosphorylated on serine 21.

Immunogen

KLH-conjugated linear peptide corresponding to 10 amino acids surrounding phosphoserine 21 from the N-terminal region of human GSK-3a .

Application

Quality Control Testing

Evaluated by Western Blotting in lysate from HEK293 cells treated with EGF.

Western Blotting Analysis: A 1:10,000 dilution of this antibody detected GSK-3a phosphorylated on serine 21 in lysate of HEK293 cells overnight starved and treated with epidermal growth factor (50 ng/mL; 10 min.).

Tested applications

Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected phospho-GSK-3a-Ser21 in lysate from NIH3T3 cells treated with PDGF.

Peptide Inhibition Assay:: Target band detection in a lysate from HEK293 cells treated with epidermal growth factor (50 ng/mL; 10 min) was prevented by preblocking of a representative lot with the immunogen phosphopeptide, but not the corresponding non-phosphopeptide.

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected phospho-GSK-3a-Ser21 in human breast cancer tissue sections.

Immunocytochemistry Analysis: A 1:1,000 dilution from a representative lot detected phospho-GSK-3a-Ser21 in Hek293 treated with EGF cell line.

Flow Cytometry Analysis: 0.1 μg from a representative lot detected phospho-GSK-3a-Ser21 in HEK293 cells treated with EGF.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

Target description

Glycogen synthase kinase-3 alpha (UniProt: P49840; also known as EC:2.7.11.26, GSK-3 alpha, Serine/threonine-protein kinase GSK3A) is encoded by the GSK3A gene (Gene ID: 2931) in human. GSK-3 is a multifunctional serine/threonine kinase, is a key regulator of numerous signaling pathways during embryogenesis and in metabolic control. Two isoforms of GSK-3 are reported in mammals: a 51 kDa GSK-3a and a 47 kDa GSK-3b. These two isoforms exhibit about 98% homology in their kinase domains but share only about 36% identity in the last 76 C-terminal amino acid residues. GSK-3a contains a glycine-rich extension at its N-terminal. It is constitutively active in cells and is regulated through inhibition of its activity. It shows a preference for target proteins that are pre-phosphorylated at a priming residue located C-terminal to the site of GSK-3 phosphorylation. Priming phosphorylation, although not absolutely required, enhances the efficiency of phosphorylation of most GSK-3 substrates. Phosphorylation of a threonine residue in the activation loop (T-loop) is considered to be essential for its activity. The T-loop of GSK-3a is phosphorylated at Tyr279 and GSK-3b at Tyr216, which play a role in forcing open the substrate-binding site of the enzyme. A primary mechanism of GSK3 activity regulation is phosphorylation of N-terminal serine residues (Serine 21 in GSK-3a and serine 9 in GSK-3b). Phosphorylation of these sites is inhibitory to GSK3 kinase activity because the phosphorylated N-terminus acts as a competitive inhibitor for primed substrates. This ZooMAb^® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.

Physical form

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS, 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.

Reconstitution

300 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Storage and Stability

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Legal Information

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.